We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

55 hedge funds and large institutions have $53.9M invested in Galectin Therapeutics in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 4

328% more capital invested

Capital invested by funds: $12.6M → $53.9M (+$41.3M)

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

67% more funds holding

Funds holding: 33 → 55 (+22)

61% less call options, than puts

Call options by funds: $3.35M | Put options by funds: $8.65M

Holders
55
Holders Change
+22
Holders Change %
+66.67%
% of All Funds
1.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
15
Reduced
5
Closed
4
Calls
$3.35M
Puts
$8.65M
Net Calls
-$5.3M
Net Calls Change
-$4.74M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$5.69M
2
CAM
Cormorant Asset Management
Massachusetts
+$4.96M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.91M
4
MP
Mangrove Partners
Connecticut
+$2.85M
5
EI
EAM Investors
California
+$2.31M

Top Sellers

Rank Fund Capital Flow
1
CCA
Catalyst Capital Advisors
New York
-$1.65M
2
Neuberger Berman Group
Neuberger Berman Group
New York
-$673K
3
DADC
D.A. Davidson & Co
Montana
-$602K
4
WAM
Wolverine Asset Management
Illinois
-$447K
5
LOM
Loeb Offshore Management
New York
-$90K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$7.66M +$5.69M +399,400 +397%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.76M +$1.91M +134,365 +44%
CAM
3
Cormorant Asset Management
Massachusetts
$5.33M +$4.96M +348,000 New
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$4.03M +$2.91M +204,665 +348%
MP
5
Mangrove Partners
Connecticut
$3.06M +$2.85M +200,000 New
EI
6
EAM Investors
California
$2.48M +$2.31M +161,935 New
Neuberger Berman Group
7
Neuberger Berman Group
New York
$2.47M -$673K -47,250 -23%
DADC
8
D.A. Davidson & Co
Montana
$2.31M -$602K -42,307 -22%
DCM
9
Driehaus Capital Management
Illinois
$2.04M +$1.9M +133,187 New
Macquarie Group
10
Macquarie Group
Australia
$2.01M +$1.87M +131,500 New
Morgan Stanley
11
Morgan Stanley
New York
$1.41M +$1.06M +74,266 +420%
Allianz Asset Management
12
Allianz Asset Management
Germany
$1.36M +$1.26M +88,660 New
BCA
13
Benchmark Capital Advisors
New York
$1.3M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.13M +$17.1K +1,203 +2%
Millennium Management
15
Millennium Management
New York
$1.08M +$1M +70,475 New
GT
16
Glenmede Trust
Pennsylvania
$989K – – –
CS
17
Credit Suisse
Switzerland
$989K +$737K +51,777 +403%
BFA
18
BlackRock Fund Advisors
California
$937K +$212K +14,861 +32%
U
19
UBS
Switzerland
$887K +$791K +55,581 +2,389%
SFM
20
Soros Fund Management
New York
$738K +$686K +48,200 New
Northern Trust
21
Northern Trust
Illinois
$616K +$68.7K +4,825 +14%
RFC
22
Russell Frank Company
Washington
$507K +$620K +43,558 New
PAM
23
Panagora Asset Management
Massachusetts
$488K +$454K +31,866 New
HCM
24
Highbridge Capital Management
New York
$474K +$441K +30,973 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$323K – – –
1
2 3

GALT Hedge Fund Activity: Q1 2014 in Review

55 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2014, worth a combined $53.9M — up 328% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new GALT positions and 4 closed out — a net gain of 22 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $5.69M. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $1.65M sold.

  • 55 institutional investors held Galectin Therapeutics (GALT) as of Q1 2014, up from 33 in Q4 2013.
  • Funds reported $53.9M of Galectin Therapeutics stock for Q1 2014, up 328% quarter-over-quarter.
  • 26 funds opened new Galectin Therapeutics positions in Q1 2014 and 4 closed out, a net change of +22 holders.
  • The largest Galectin Therapeutics buyer in Q1 2014 was Baker Bros. Advisors, an estimated $5.69M added.
  • The largest Galectin Therapeutics seller in Q1 2014 was Catalyst Capital Advisors, an estimated $1.65M sold.

Based on aggregated 13F filings for Q1 2014.